Akari Therapeutics, Plc has selected WuXi XDC Cayman Inc. as its contract development and manufacturing organization $(CDMO)$ partner for the GMP manufacturing of AKTX-101, Akari's lead antibody drug conjugate $(ADC)$ program. The collaboration aims to support IND-enabling activities and the production of GMP-grade material for a planned Phase 1 first-in-human clinical trial. WuXi XDC will provide end-to-end ADC development and manufacturing services, supporting Akari's clinical development timeline for AKTX-101, which is expected to begin clinical trials in late 2026 or early 2027, pending regulatory clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9616311) on December 23, 2025, and is solely responsible for the information contained therein.